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Central indicator
Resistance to BRAF and/or MEK kinase-targeting drugs in 
BRAF(V600) mutant tumors stems primarily from reactivation 
of the mitogen-activated protein kinase (MAPK) signal transduc-
tion pathway, activation of extracellular signal-regulated kinase 
(ERK)-independent PI(3)K-AKT-mTOR signaling, or alterations 
in the caspase-dependent apoptotic cascade. These three path-
ways regulate formation of the eIF4F eukaryotic translation ini-
tiation complex. In a recent report, Boussemart and colleagues 
found that persistence of the eIF4F complex is associated with 
drug resistance in melanoma, colon, and thyroid cancer cells. 
Clinically, formation of the eIF4F complex was decreased in 
BRAF inhibitor–responsive melanoma tumors and increased 
in resistant metastatic tumors. Thus, eIF4F complex formation 
may serve as an indicator of anti-BRAF and anti-MEK cancer 
therapy resistance, and inhibition of eIF4F complex formation 
using small-molecule inhibitors or flavagline derivatives may be 
an option to target eIF4F in combination with BRAF inhibition 
for successful cancer treatment in the face of drug resistance. 
(Nature 513:105–9, 2014) Selected by T. Schwarz
When the medicine’s not working anymore
Recent advances in melanoma therapy, including ipilimumab 
and MAPK inhibitors, have proved successful; however, few 
options are available for nonresponding patients. In addition, 
as mentioned above, combination therapy with BRAF and 
MEK inhibitors has shown a 76% response rate, but most of 
these BRAF-mutant patients develop resistance to the inhibi-
tors. A selective humanized monoclonal antibody (pembro-
lizumab) to programmed death receptor 1 (PD-1) has been 
quite effective in inducing long-lasting objective responses 
in advanced melanoma patients. Thus, Robert and colleagues 
assessed the clinical benefits of such treatment in 173 patients 
with BRAF-mutant advanced melanoma that had progressed 
after ipilimumab treatment and BRAF or MEK inhibitors. In 
this international, multicenter, randomized dose-comparison 
expansion of a phase I trial, pembrolizumab treatment was 
found to be an effective and safe treatment for patients with 
these characteristics. Doses of 2 or 10 mg/kg every 3 weeks 
induced a long-lasting response, indicating that this antibody 
is a useful option for patients with limited remaining treatment 
options. (Lancet 384:1109–17, 2014) Selected by T. Schwarz
Field medicine
Impetigo, which is caused by Streptococcus pyogenes and 
Staphylococcus aureus, is a considerable burden in resource-
limited settings and can lead to severe, life-threatening sequelae. 
Intramuscular benzathine benzylpenicillin has been used effec-
tively since the 1970s to treat extensive impetigo in tropical set-
tings. More recently, oral cotrimoxazole, which is effective for 
methicillin-resistant S. aureus infections, was demonstrated to be 
effective for S. pyogenes as well. In an open-label, randomized, 
controlled, noninferiority trial to compare the efficacy of the two 
impetigo treatment regimens in Indigenous Australian children, 
Bowen and colleagues demonstrated noninferiority of short-
course oral cotrimoxazole, either once daily for 5 days or twice 
daily for 3 days, to intramuscular benzathine benzylpenicillin to 
treat impetigo caused by S. pyogenes and/or S. aureus. Thus, short-
course cotrimoxazole—which is widely available, palatable, 
painless, practical, easily administered, and inexpensive—should 
be considered for treating impetigo in developing regions, reduc-
ing transmission for control of an important global skin infection. 
(Lancet, published online 27 August 2014; doi:10.1016/S0140-
6736(14)60841-2) Selected by H. Williams
Unique microsignature
The abundant microbial ecosystem of the human skin exhib-
its extreme diversity due to the varied microenvironments on 
the surface of the skin. Oh and colleagues recently reported a 
systematic metagenomic analysis of skin from 18 sites from 15 
healthy individuals. Interestingly, the skin microbial metagenome 
revealed taxonomic and functional diversity that was dependent 
on biogeography as well as on individuality. In fact, using mul-
tikingdom taxonomy, these investigators could differentiate the 
15 donors with >80% accuracy. The skin carried higher viral and 
fungal species than did other body sites, as well as a mix of com-
mon skin species strains. Reference-free resources for multiking-
dom analyses generated by adaptive assembly provide a toolkit 
for future investigations into disease states and genetic signa-
tures. (Nature 514:59–64, 2014) Selected by M. Amagai
Renew, regenerate, and recycle
In a recent review, Clevers and colleagues described the func-
tions of Wnt signaling in stem-cell control and tissue renewal 
and regeneration. Stem cells are required for continuous tis-
sue maintenance and renewal, and the activity of these cells is 
often directed by specific factors in the microenvironment. Wnt 
signaling, which proceeds via lipid-modified molecules, sig-
nals primarily over a short range between adjacent cells. Such 
specificity results in physically restrained signaling, which influ-
ences the nearby developmental and regenerative capabili-
ties without far-reaching effects. In the continually regenerating 
interfollicular epidermis, basal stem cell proliferation, which is st 
ochastic, appears to be controlled by Wnt signaling as basal cells 
produce their own Wnt ligands, suggesting a form of autocrine 
regulation in this system. Thus, Wnt signaling controls stem cell 
behavior within the spatial confines of the niche in order to limit 
the stem cell compartment and to prevent unnecessary stem 
cell expansion. Exclusion from the niche may remove access 
to Wnt and induce differentiation, but, importantly, these stem 
cells retain the flexibility to regain stemness upon tissue dam-
age. (Science, published online 3 October 2014; doi:10.1126/ 
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